Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK. Lichterfeld M, et al. Among authors: fenske s. HIV Med. 2002 Jan;3(1):37-43. doi: 10.1046/j.1464-2662.2001.00091.x. HIV Med. 2002. PMID: 12059949 Free article. Clinical Trial.
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H. Rockstroh JK, et al. Among authors: fenske s. AIDS. 2000 Jun 16;14(9):1181-5. doi: 10.1097/00002030-200006160-00015. AIDS. 2000. PMID: 10894282 Clinical Trial.
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK. Vogel M, et al. Among authors: fenske s. Eur J Med Res. 2010 Mar 30;15(3):102-11. doi: 10.1186/2047-783x-15-3-102. Eur J Med Res. 2010. PMID: 20452894 Free PMC article. Clinical Trial.
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoeper K, Horst HA, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink HJ, Hamouda O, Bartmeyer B; ClinSurv Study Group. Stoll M, et al. PLoS One. 2011;6(9):e23946. doi: 10.1371/journal.pone.0023946. Epub 2011 Sep 9. PLoS One. 2011. PMID: 21931626 Free PMC article.
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group. Pett SL, et al. HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31. HIV Med. 2011. PMID: 20812949 Free PMC article. Clinical Trial.
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators. Wyen C, et al. J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29. J Antimicrob Chemother. 2011. PMID: 21715435 Free article.
105 results